Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 8/20 | 0.42 |
| ▸ | JAK1 | P23458 | 8/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16258764 | 0.84 | SMN1; SMN2 (0.48) | ALOX15TSHRHSD17B10GFERGAA | |
| SCHEMBL21078192 | 0.78 | THRB (0.52) | THRBALOX15TSHRHSD17B10JAK2 | |
| SCHEMBL18909230 | 0.76 | THRB (0.53) | THRBALOX15TSHRHSD17B10GAA | |
| SCHEMBL22875303 | 0.74 | GFER (0.44) | GFER | |
| SCHEMBL19275281 | 0.73 | THRB (0.50) | THRBALOX15TSHRHSD17B10GAA | |
| SCHEMBL16565653 | 0.73 | GFER (0.48) | HSD17B10JAK2JAK1GFER | |
| SCHEMBL8429458 | 0.70 | HSD17B10 (0.66) | THRBALOX15TSHRHSD17B10GAA | |
| SCHEMBL13149530 | 0.70 | KMT2A (0.47) | JAK2JAK1GFER | |
| SCHEMBL21567934 | 0.70 | THRB (0.50) | THRBALOX15TSHRHSD17B10GAA | |
| SCHEMBL18909453 | 0.69 | ALOX15 (0.55) | THRBALOX15TSHRHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-9873709-B2 | Triazolopyridine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| WO-2015032286-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | THRB 1155/4885ALOX15 2649/4885TSHR 2621/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | THRB 1155/4885ALOX15 2649/4885TSHR 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.